22 results about "Furosemide" patented technology

Disclosed herein, in part, are liquid pharmaceutical formulations comprising furosemide or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable excipients, and a pharmaceutically acceptable buffer. Methods of treating congestion, edema, fluid overload, or hypertension in a patient in need thereof are also provided.

Disclosed herein, in part, are liquid pharmaceutical formulations comprising furosemide or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable excipients, and a pharmaceutically acceptable buffer. Methods of treating congestion, edema, fluid overload, or hypertension in a patient in need thereof are also provided.

Disclosed herein, in part, are liquid pharmaceutical formulations comprising furosemide or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable excipients, and a pharmaceutically acceptable buffer. Methods of treating congestion, edema, fluid overload, or hypertension in a patient in need thereof are also provided.

Disclosed herein, in part, are liquid pharmaceutical formulations comprising furosemide or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable excipients, and a pharmaceutically acceptable buffer. Methods of treating congestion, edema, fluid overload, or hypertension in a patient in need thereof are also provided.

Disclosed herein, in part, are liquid pharmaceutical formulations comprising furosemide or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable excipients, and a pharmaceutically acceptable buffer. Methods of treating congestion, edema, fluid overload, or hypertension in a patient in need thereof are also provided.

The invention belongs to the technical field of biological medicine, and particularly provides application of flufenidone in preparation of a medicine for preventing or treating left heart failure. The research finds that the flufenidone has the effects of relieving myocardial cell hypertrophy under a heart failure cell model and relieving myocardial hypertrophy, fibrosis and heart function deterioration of an aortic constriction animal model. According to the present invention, further research results show that fluorofenidone is directly combined with SERCA2a through Q758, D812 and E917 residues of SERCA2a so as to inhibit recognition, combination and polyubiquitination effects of WWP1 on SERCA2a, such that the protein level and the activity of SERCA2a are stabilized so as to achieve the chronic left heart failure treatment purpose. Therefore, the flufenidone serving as an active ingredient has good application prospect and application value in research and development of novel medicines for treating chronic left heart failure.

The present invention provides methods relating to the discovery of olfactomedin 4 (OLFM4) as a biomarker for acute kidney injury (AKI) and need for renal replacement therapy, and further as a biomarker for responsiveness to the furosemide stress test (FST). The methods described here are useful in clinical decision support and personalized therapy for AKI, as well as for clinical trial design.

The application belongs to the technical field of medicine synthesis, and particularly relates to a preparation method of furosemide. The preparation method of furosemide comprises the following steps: chlorosulfonation: reacting chlorosulfonic acid and 2,4-dichlorobenzoic acid, hydrolyzing, filtering, and obtaining 2,4-dichloro-5-sulfonyl chlorobenzoic acid; amination: adding 2,4-dichloro-5-sulfonyl chlorobenzoic acid into ammonia water, reacting, neutralizing, filtering, purifying, and obtaining 2,4-dichloro-5-sulfonamidobenzoic acid; condensation: reacting 2-furfurylamine and 2,4-dichloro-5-sulfonamidobenzoic acid, and obtaining furosemide crude product; decolorization: adding the furosemide crude product into a saturated sodium bicarbonate solution, adding activated carbon for decolorization, neutralizing, and crystallizing, and thus furosemide product is obtained. The raw material used in the application is easy to obtain and low in price, the comprehensive reaction period is short, the amount of hazardous waste generated is small, the prepared furosemide is high in purity and high in total yield, the comprehensive cost of the whole preparation process is low, and the application is suitable for industrial production.

A pharmaceutical composition and a method of administering the pharmaceutical composition to a patient suffering from edema, heart failure, kidney or liver disease or having symptoms thereof is disclosed. The pharmaceutical composition includes furosemide, or a pharmaceutically acceptable salt, hydrate or ester thereof and tris(hydroxymethyl)aminomethane. The furosemide is present in the pharmaceutical composition at a concentration from about 10 mg / mL to about 30 mg / mL and the tris(hydroxymethyl)aminomethane is present at a concentration of less than or equal to 40 mM. The pH value of the pharmaceutical composition is maintained between about 8.0 and about 8.5 for parenteral administration.

A production process and purification method for furosemide. The process comprises the following steps: S1, adding a crude furosemide product to an inorganic alkali solution, sufficiently reacting same, decolorizing and filtering same, adjusting the pH value of a filtrate with an acid solution to create acidic conditions, subjecting same to crystallization, and then filtering and washing same to obtain a solid substance; and S2, adding the solid substance to a recrystallization solvent, heating same to reflux same in a boiling state until the temperature of the solution is constant, then filtering same while the solution is still hot, transferring the resulting filtrate into a crystallization kettle, heating the solution to the boiling point temperature thereof, stopping heating, setting the pressure of the crystallization kettle to be 3-60 kPa, conducting crystallization, extracting the evaporated solvent, and after the solution in the crystallization kettle stops boiling, cooling the solution to 10-15ºC by using circulating cooling water, continuing crystallization, and then conducting filtering, washing and drying to obtain a finished furosemide product. The purification method provided can avoid the cold wall precipitation of crystals, reduce the generation of waste liquid, and significantly improve the purity and yield of furosemide.

A heart failure management system for a patient includes a plurality of sensors including at least one implantable pressure sensor positioned within the heart to capture synchronized left and right heart pressure waveforms, transmitted via one or more transmitters to a receiver. Control circuitry receives these waveforms and processes them using a machine learning medication dosage management model, trained on historical left and right heart pressure logs, volume status metrics (e.g., weight, fluid intake, symptoms), and / or ground truth dosage logs for certain heart failure treatment medications, such as a blood pressure reducing medication (e.g., ARNI) and an intravascular volume reducing medication (e.g., Lasix). The model can generate real-time dosage recommendations, systemic blood pressure, and volume load predictions in real-time, enabling precise, data-driven treatment adjustments aligned with clinical guidelines, supporting timely clinical decisions or automated medication dispensing to optimize patient outcomes and reduce hospitalization risks.

Materials and methods for treating hypertension (including resistant hypertension) with a combination of an M-atrial natriuretic peptide (MANP) and a diuretic agent (e.g., furosemide) are described herein.

This invention discloses a production process and purification method for furosemide, comprising the following steps: S1, adding crude furosemide to an inorganic alkaline solution, allowing it to react fully, decolorizing and filtering, adjusting the pH of the filtrate to acidic conditions with acid to induce crystallization, filtering and washing to obtain a solid substance; S2, adding the solid substance to a recrystallization solvent, heating and refluxing it at boiling point until the solution temperature remains constant, filtering while hot, transferring the filtrate to a crystallization vessel, heating the solution to its boiling point and then stopping heating, setting the pressure of the crystallization vessel to 3-60 kPa to induce crystallization, and extracting the evaporated solvent. After the solution in the crystallization vessel stops boiling, cooling the solution to 10-15°C using circulating cooling water to continue crystallization, filtering, washing, and drying to obtain the finished furosemide product. The purification method of this invention can avoid cold wall precipitation of crystals, reduce waste liquid generation, and significantly improve the purity and yield of furosemide.

The present teachings relate to liquid pharmaceutical formulations of furosemide, where the pharmaceutical formulations include a molar excess of tris(hydroxymethyl)aminomethane to furosemide, have a pH in the range of 7 to 8.5, and a concentration of tris(hydroxymethyl)aminomethane greater than or equal to about 50 mM. The present teachings can improve the stability of liquid pharmaceutical formulations including furosemide and the suitability of such pharmaceutical formulations for subcutaneous administration or delivery.

A pharmaceutical composition and a method of administering the pharmaceutical composition to a patient suffering from edema, heart failure, kidney or liver disease or having symptoms thereof are disclosed. The pharmaceutical composition includes furosemide, or a pharmaceutically acceptable salt, hydrate or ester thereof and a cyclodextrin.

The invention provides a synthesis method of 2-amino-4-chloro-5-(sulfonylamino)-N-(o-tolyl) benzamide, and belongs to the technical field of medicine synthesis. According to the method I, according to the property of a substrate 2, 4-dichloro-5-sulfonamido benzoic acid, the reaction temperature is controlled, the substrate reacts with benzylamine, the reaction is promoted to be fully carried out, raw material residues in a mixed solution of a reaction system are reduced, and after a first amidation reaction and benzyl removal, the 2, 4-dichloro-5-sulfonamido benzoic acid is obtained; the 2-amino-4-chloro-5-(sulfonylamino)-N-(o-tolyl) benzamide with high yield is obtained by adding the 2-amino-4-chloro-5-(sulfonylamino)-N-(o-tolyl) benzamide into a solvent; according to the second method, furothiazide is used as an initial raw material, and 2-amino-4-chloro-5-(sulfonylamino)-N-(o-tolyl) benzamide is obtained through a second amidation reaction and methyl furan removal. According to the method, the conversion rate and the yield of the raw materials are improved, raw material residues are effectively controlled, impurities are reduced, the reaction steps are simplified, and the safety during operation is improved.

The invention discloses a new application of a sodium-glucose cotransporter 2 inhibitor in preparation of drugs for treatment and / or adjuvant treatment of ascites due to cirrhosis. The sodium-glucose cotransporter 2 inhibitor disclosed by the invention can take effect together with furosemide, effectively increases urine sodium and urine excretion of intractable or intractable ascites due to cirrhosis caused by diuretic resistance, improves the uncomfortable symptoms of abdominal distension of the patients, reduces the total amount of ascites, and is good in treatment effect and free of toxic and side effects. The treatment dilemma that the ascites of the patients cannot be effectively reduced by medicines in the prior art is effectively solved.

The invention belongs to the technical field of medicine synthesis, and particularly relates to a brand-new efficient furosemide-D5 synthesis method which comprises the following steps: starting from a simple raw material trans-2, 3-dibromo-2-butene-1, 4-diol and the like, performing oxidative cyclization, low-temperature metallization-carboxylation, lewis acid catalytic bromination, catalytic deuteration, LiAlD4 reduction and the like to obtain furosemide-D5. And the furosemide-D5 molecule is efficiently synthesized by a relatively short linear step. The synthesis reaction raw materials are easy to obtain, the operation is simple and safe, less waste is generated, the isotope raw material utilization rate is high, and the deuterium atoms are subjected to precise fixed-point substitution reaction.

This invention provides a furosemide-triamterene compound thermosensitive hydrogel oral formulation, its preparation method, detection method, and application, belonging to the field of veterinary formulation technology. The formulation, by mass percentage, comprises furosemide 0.2%-2.0%, triamterene 0.2%-2.0%, an adhesion thickener 0.5%-2.0%, a thermosensitive hydrogel matrix 15%-30%, and moisturizing stabilizers, flavoring agents, and preservatives. The gelation temperature is 28-32℃, the maximum adhesion force to the gastric mucosa is 0.15N-0.35N, and the adhesion work is 5mJ-15mJ. This invention employs a cold-dissolution method, a process free of organic solvents, and simultaneously determines the content of two drugs using HPLC. The formulation flows at 2-8°C and rapidly gels and adheres at 37°C, achieving synergistic diuresis and potassium balance maintenance. It features precise dosage, good palatability, and stable blood drug concentrations, making it suitable for preparing veterinary drugs for canine and feline diuresis, swelling reduction, and potassium balance maintenance. This invention solves the problems of inaccurate dosage, poor compliance, and lack of quality control in existing pet diuretic preparations, ensuring stable and controllable quality and suitability for large-scale production.

To provide concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same.SOLUTION: Disclosed herein, in part, are liquid pharmaceutical formulations comprising furosemide or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable excipients, and a pharmaceutically acceptable buffer. Methods of treating congestion, edema, fluid overload, or hypertension in a patient in need thereof are also provided.SELECTED DRAWING: None

The invention relates to the technical field of medical instruments, and discloses a composite hyaluronic acid beauty fluid formula, which comprises 2 ml of levocarnitine, 2 ml of furosemide, 2 ml of gastrodin, 1 ml of dexamethasone, 3 ml of triamcinolone acetonide, 1 ml of auxin, 3 ml of lidocaine, and 100 ml of saline water. Through two-way regulation and control, tissue regeneration is not stimulated, the healing property is high, and the problem caused by excessive filling of regenerative materials can be rapidly solved.

The application belongs to the technical field of medicine synthesis, and particularly relates to a novel and efficient furosemide-D5 synthesis method. The furosemide-D5 molecule is efficiently synthesized in a short linear step from simple raw materials such as trans-2,3-dibromo-2-butene-1,4-diol and the like through an oxidation cyclization, a low-temperature metallization-carboxylation, a Lewis acid catalysis bromination, a catalytic deuterium decomposition and a LiAlD4 reduction and the like. In the application, the synthesis reaction raw materials are easy to obtain, the operation is simple and safe, waste is less, the isotopic raw material utilization rate is high, and the precise site substitution reaction of deuterium atoms is realized.